Drug Profile


Alternative Names: JNJ-64091742; MK-4827; niraparib hydrochloride; Zejula

Latest Information Update: 10 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck & Co
  • Developer Dana-Farber Cancer Institute; European Network of Gynaecological Oncological Trial Groups; European Organisation for Research and Treatment of Cancer; Hoosier Cancer Research Network; Janssen; Merck & Co; Sarcoma Alliance for Research through Collaboration; TESARO; University of Utah
  • Class Antineoplastics; Benzamides; Indazoles; Piperidines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase III Breast cancer
  • Phase II Prostate cancer
  • Phase I Ewing's sarcoma; Solid tumours
  • No development reported Haematological malignancies

Most Recent Events

  • 08 Aug 2017 TESARO plans to launch niraparib in Fallopian tube cancer (Recurrent, Second-line therapy or greater), Ovarian cancer (Recurrent, Second-line therapy or greater) and Peritoneal cancer (Recurrent, Second-line therapy or greater) in Europe by end-2017
  • 08 Aug 2017 TESARO initiates an expanded-access programme for Ovarian cancer (Recurrent, Second-line therapy) in Europe
  • 27 Jul 2017 Niraparib licensed to Takeda for all indications in Japan and for all indications excluding Prostate cancer in South Korea, Taiwan, Russia and Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top